Table 3.
Cost-effectiveness results per person from base case and scenario analyses (2016 US$)
| Country | Base case analysis | Scenario analyses | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Strategy | Healthcare provider perspective | Societal perspective | PQ14 and TQ efficacy equal to PQ7 | |||||||||||||||
| G6PD screening | Males | Females | Cost | Incremental costs | DALYs | DALYs averted | ICER | Cost | Incremental costs | DALYs | DALYs averted | ICER | Cost | Incremental costs | DALYs | DALYs averted | ICER | |
| Afghanistan | No | PQ14 | $6.1 | – | 0.0140 | – | – | $18.6 | – | 0.0140 | – | – | $5.8 | – | 0.0131 | – | – | |
| Yes | TQ | PQ7 | $11.5 | $5.4 | 0.0091 | 0.0050 | $1,089 | $22.6 | $4.0 | 0.0091 | 0.0050 | $815 | $10.2 | $4.5 | 0.0077 | 0.0055 | $814 | |
| Yes | TQ | PQ14 | $11.7 | – | 0.0096 | – | Dominated | $23.2 | – | 0.0096 | – | Dominated | $10.3 | – | 0.0080 | – | Dominated | |
| Yes | TQ | Referral for TQ | $12.9 | – | 0.0095 | – | Dominated | $24.8 | – | 0.0095 | – | Dominated | $11.3 | – | 0.0079 | – | Dominated | |
| Ethiopia | No | No radical cure | $11.6 | – | 0.0181 | – | – | $35.5 | – | 0.0181 | – | Dominated | $11.6 | – | 0.0181 | – | – | |
| Yes | TQ | PQ7 | $15.2 | $3.6 | 0.0104 | 0.0077 | $466 | $30.9 | – | 0.0104 | – | Cost-saving | $13.7 | $2.1 | 0.0089 | 0.0092 | $228 | |
| Yes | TQ | PQ14 | $15.8 | – | 0.0119 | – | Dominated | $33.0 | – | 0.0119 | – | Dominated | $14.0 | – | 0.0101 | – | Dominated | |
| Yes | TQ | Referral for TQ | $17.9 | – | 0.0115 | – | Dominated | $35.6 | – | 0.0115 | – | Dominated | $15.8 | – | 0.0096 | – | Dominated | |
| Indonesia | No | PQ14 | $11.6 | – | 0.0124 | – | – | $83.2 | – | 0.0124 | – | – | $10.9 | – | 0.0117 | – | – | |
| Yes | TQ | PQ7 | $30.2 | $18.6 | 0.0082 | 0.0042 | $4,443 | $95.0 | $11.9 | 0.0082 | 0.0042 | $2,828 | $28.0 | $17.1 | 0.0073 | 0.0044 | $3,925 | |
| Yes | TQ | PQ14 | $31.2 | – | 0.0089 | – | Dominated | $98.6 | – | 0.0089 | – | Dominated | $28.4 | – | 0.0079 | – | Dominated | |
| Yes | TQ | Referral for TQ | $34.4 | – | 0.0087 | – | Dominated | $102.3 | – | 0.0087 | – | Dominated | $31.4 | – | 0.0076 | – | Dominated | |
| Vietnam | No | PQ14 | $11.7 | – | 0.0160 | – | – | $52.3 | – | 0.0160 | – | Dominated | $11.2 | – | 0.0152 | – | Dominated | |
| Yes | TQ | PQ7 | $12.6 | $0.9 | 0.0092 | 0.0068 | $127 | $44.4 | – | 0.0092 | – | Cost-saving | $11.2 | – | 0.0077 | – | Cost-saving | |
| Yes | TQ | PQ14 | $12.8 | – | 0.0096 | – | Dominated | $45.1 | – | 0.0096 | – | Dominated | $11.2 | – | 0.0080 | – | Dominated | |
| Yes | TQ | Referral for TQ | $13.1 | – | 0.0095 | – | Dominated | $45.8 | – | 0.0095 | – | Dominated | $11.6 | – | 0.0079 | – | Dominated | |
DALYs = disability-adjusted life-years; ICER = incremental cost-effectiveness ratio; G6PD = glucose-6-phosphate dehydrogenase; PQ7 = 7-day high-dose primaquine; PQ14 = 14-day low-dose primaquine; TQ = tafenoquine. The first strategy listed for each country is current usual care. See Supplemental Table 1 for results by sex.